FDA Grants Priority Review for Roche Drug to Treat Rare Kidney Disease

Roche's Gazyva/Gazyvaro has received Priority Review status from the FDA for its potential use in treating primary membranous nephropathy, a chronic autoimmune kidney disease. This decision follows positive Phase III trial results indicating the drug's superiority over existing treatments. If approved, it would mark the first FDA-sanctioned therapy for this condition, addressing a significant unmet medical need.